Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy-Reference-Cited by-同舟云学术

Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy

Published:2023-12-15 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Shi Mengting¹²³⁴,Sun Dongchen¹²³⁴,Ma Xilun⁵,Liu Jiaqing²³⁶,Zhang Yaxiong¹²³⁴,Liu Tingting¹²³⁴,Chen Xueyuan¹²³⁴,Mo Silang¹²³⁴,Zhao Yuanyuan¹²³,Zhang Li¹²³

Affiliation:

1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

2. State Key Laboratory of Oncology in South China, Guangzhou, China

3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

4. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China

5. Department of Radiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China

6. Department of Intensive Care Unit, Sun Yat-sen University Cancer Center, Guangzhou, China

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2294579

Reference22 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

3. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)

4. Leptomeningeal Metastasis

5. An epidemiologic and clinical study of nasopharyngeal carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association ofMatrix Metalloproteinase-9Genotypes With Nasopharyngeal Carcinoma Risk;In Vivo;2024